• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 3. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Chlorobenzenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Chlorobenzenes

Compound Introduction: (1S)-1-(3-bromo-4-chlorophenyl)ethan-1-ol (CAS No. 1567895-16-2)

(1S)-1-(3-bromo-4-chlorophenyl)ethan-1-ol is a meticulously crafted organic compound characterized by its distinct structural and chemical properties. This compound, identified by the CAS number 1567895-16-2, has garnered significant attention in the field of pharmaceutical research due to its potential applications in drug development and synthetic chemistry. The presence of both bromo and chloro substituents on the aromatic ring imparts unique reactivity, making it a valuable intermediate in the synthesis of more complex molecules.

The stereochemistry of this compound, specifically the (1S) configuration, plays a crucial role in its biological activity. Chirality is a fundamental aspect of many pharmacologically active compounds, and the precise arrangement of atoms can significantly influence how a molecule interacts with biological targets. In recent years, there has been a growing emphasis on the development of enantiomerically pure compounds to enhance therapeutic efficacy while minimizing adverse effects.

Recent studies have highlighted the importance of 3-bromo-4-chlorophenyl motifs in medicinal chemistry. These structural features are often found in a variety of bioactive molecules, including kinase inhibitors and antiviral agents. The bromo and chloro groups provide electrophilic centers that can be readily functionalized through various chemical reactions, such as cross-coupling reactions, allowing for the construction of diverse molecular frameworks.

In the context of drug discovery, (1S)-1-(3-bromo-4-chlorophenyl)ethan-1-ol serves as a versatile building block. Researchers have leveraged its reactivity to develop novel analogs with enhanced pharmacological properties. For instance, derivatives of this compound have been explored as potential inhibitors of enzymes involved in cancer metabolism. The ability to modify both the aromatic ring and the aliphatic side chain offers a broad spectrum of opportunities for structural optimization.

The synthesis of this compound typically involves multi-step organic transformations, starting from commercially available precursors. Key steps often include halogenation reactions to introduce the bromo and chloro substituents, followed by stereochemical control during the formation of the chiral center. Advanced synthetic methodologies, such as asymmetric hydrogenation or enzymatic resolution, are employed to achieve high enantiomeric purity.

From a computational chemistry perspective, the molecular properties of (1S)-1-(3-bromo-4-chlorophenyl)ethan-1-ol have been extensively studied using density functional theory (DFT) and other quantum mechanical methods. These calculations provide insights into its electronic structure, stability, and reactivity. Understanding these properties is essential for designing efficient synthetic routes and predicting its behavior in biological systems.

The pharmaceutical industry has shown particular interest in compounds containing 3-bromo-4-chlorophenyl moieties due to their reported bioactivity against various diseases. Preclinical studies have demonstrated that derivatives of this scaffold exhibit promising effects in models of inflammation and neurodegeneration. The combination of structural diversity and functional flexibility makes it an attractive candidate for further investigation.

In conclusion, (1S)-1-(3-bromo-4-chlorophenyl)ethan-1-ol (CAS No. 1567895-16-2) is a significant compound in modern medicinal chemistry. Its unique structural features, coupled with its stereochemical precision, make it a valuable tool for drug discovery and synthetic applications. As research continues to uncover new therapeutic targets and methodologies, this compound is poised to play an increasingly important role in the development of next-generation pharmaceuticals.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)